# Who does ABL Bio pay? Who are its key suppliers?
Canonical: https://valuechain.wiki/abl-bio · Facet: suppliers · Updated: 2026-07-12T04:17:23.858+00:00 · Source: ValueChain.wiki (cited money-flow graph)

**Citable summary**: ABL Bio's confirmed suppliers/cost counterparties include 브리스톨 마이어스 스퀴브 plus 1 undisclosed/aggregate relationship. Per the valuechain.wiki graph: 2 cost edges, backed by 1 dated sources, 1 of them primary filings (as of 2026-07-12).

### 항체 위탁생산·임상 외주용역(CMO/CRO) (high)
- metric: Amount 69,255,185,000원 · 연구개발 외주용역비 · 2025 outsourced-service cost KRW 69.3bn
- note: With no large-scale production of its own, ABL Bio outsources preclinical and clinical antibody supply to contract manufacturers (CMOs) and runs experiments through outside research organisations (CROs). Outsourced-service cost reached 69.3 billion won in 2025, 74% of the 93.0 billion won total R&D spend.
- [confirms] DART (FSS) (KO, filing, published 2026-03-12) https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260312000744: "For large-scale antibody production the company uses domestic and overseas contract manufacturers (CMOs). 2025 outsourced-service cost was KRW 69,255,185 thousand of KRW 93,013,680 thousand total R&D spend."

### 브리스톨 마이어스 스퀴브 (mid)  → /bristol-myers-squibb.md
- note: BMS supplies its checkpoint inhibitor Opdivo (nivolumab) for the triple-combination trial of ABL111 (CLDN18.2 x 4-1BB), ABL Bio's gastric-cancer bispecific. A clinical combination-supply arrangement with undisclosed value.
- [confirms] DART (FSS) (KO, filing, published 2026-03-12) https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260312000744: "Signed an Opdivo supply agreement with BMS for the ABL111 triple-combination trial"

Reverse side: https://valuechain.wiki/abl-bio/customers.md · Ripple: https://valuechain.wiki/abl-bio/ripple.md

---
Full node: https://valuechain.wiki/abl-bio.md · JSON: https://valuechain.wiki/abl-bio.json